These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16213624)

  • 41. Health technology assessment for the NHS in England and Wales.
    Woods K
    Int J Technol Assess Health Care; 2002; 18(2):161-5. PubMed ID: 12053415
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Deliberating Tarceva: A case study of how British NHS managers decide whether to purchase a high-cost drug in the shadow of NICE guidance.
    Hughes D; Doheny S
    Soc Sci Med; 2011 Nov; 73(10):1460-8. PubMed ID: 22000765
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.
    Claxton K; Sculpher M; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J; O'Hagan T
    Health Econ; 2005 Apr; 14(4):339-47. PubMed ID: 15736142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries.
    Kaló Z; Landa K; Doležal T; Vokó Z
    Eur J Cancer Care (Engl); 2012 Jul; 21(4):442-9. PubMed ID: 22510226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Review of Economic Submissions to NICE Medical Technologies Evaluation Programme.
    Alshreef A; Jenks M; Green W; Dixon S
    Appl Health Econ Health Policy; 2016 Dec; 14(6):623-634. PubMed ID: 27480537
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
    Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
    Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Has NICE been nice to cancer?
    Summerhayes M; Catchpole P
    Eur J Cancer; 2006 Nov; 42(17):2881-6. PubMed ID: 17070032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A rational framework for decision making by the National Institute For Clinical Excellence (NICE).
    Claxton K; Sculpher M; Drummond M
    Lancet; 2002 Aug; 360(9334):711-5. PubMed ID: 12241891
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD).
    Schlander M
    Curr Med Res Opin; 2007 Jan; 23(1):207-22. PubMed ID: 17261237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health technology adoption and the politics of governance in the UK.
    Milewa T
    Soc Sci Med; 2006 Dec; 63(12):3102-12. PubMed ID: 16982120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Health Technology Assessment of companion diagnostics: experience of NICE.
    Byron SK; Crabb N; George E; Marlow M; Newland A
    Clin Cancer Res; 2014 Mar; 20(6):1469-76. PubMed ID: 24634470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Making decisions on technology availability in the British National Health Service--why we need reliable models.
    Akehurst RL
    Value Health; 2003; 6(1):3-5. PubMed ID: 12535232
    [No Abstract]   [Full Text] [Related]  

  • 53. NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias.
    Brown P; Calnan M
    Med Health Care Philos; 2013 May; 16(2):281-93. PubMed ID: 22198480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The extent and quality of qualitative evidence included in health technology assessments: a review of submissions to NICE and CADTH.
    Szabo SM; Hawkins NS; Germeni E
    Int J Technol Assess Health Care; 2023 Dec; 40(1):e6. PubMed ID: 38126273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. National Institute for Health and Clinical Excellence: the Medical Technologies Evaluation Programme.
    J Med Eng Technol; 2011 Jul; 35(5):283-4. PubMed ID: 21635177
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single technology appraisals by NICE: are they delivering faster guidance to the NHS?
    Barham L
    Pharmacoeconomics; 2008; 26(12):1037-43. PubMed ID: 19014204
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance.
    Crispi F; Naci H; Barkauskaite E; Osipenko L; Mossialos E
    Appl Health Econ Health Policy; 2019 Apr; 17(2):189-211. PubMed ID: 30367349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997.
    Cooper N; Coyle D; Abrams K; Mugford M; Sutton A
    J Health Serv Res Policy; 2005 Oct; 10(4):245-50. PubMed ID: 16259692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prioritisation of specialist health care services; not NICE, not easy but it can be done.
    Anderson P; Webb P; Groves S
    Health Policy; 2017 Sep; 121(9):978-985. PubMed ID: 28797706
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.